Cargando…
ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for response stratification still need further screening. In the present study, a total of 399 patients with high-quality ctDNA profil...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452871/ https://www.ncbi.nlm.nih.gov/pubmed/34557222 http://dx.doi.org/10.3389/fgene.2021.723670 |
_version_ | 1784570163044024320 |
---|---|
author | Lu, Jun Zhang, Yanwei Lou, Yuqing Yan, Bo Zou, Benkun Hu, Minjuan Wang, Yanan Chen, Ya Yang, Zhengyu Wang, Huimin Zhang, Wei Han, Baohui |
author_facet | Lu, Jun Zhang, Yanwei Lou, Yuqing Yan, Bo Zou, Benkun Hu, Minjuan Wang, Yanan Chen, Ya Yang, Zhengyu Wang, Huimin Zhang, Wei Han, Baohui |
author_sort | Lu, Jun |
collection | PubMed |
description | Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for response stratification still need further screening. In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP2A) and clinical information were further integrated. The results suggested that the patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (–)]; and more promising predictive values were shown in the smoker subgroup and ≤ 3 metastasis subgroup. More interestingly, we found the predictor has more performance in TP53-negative cohorts [training in an independent POPLAR and OAK cohorts (n = 200), and validation in an independent MSKCC cohort (n = 127)]. Overall, this study provides a predictor, UBL biological process gene mutation status, not only for identifying NSCLC patients who may respond to atezolizumab therapy but also for screening out the potential NSCLC responders who received other immune checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-8452871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84528712021-09-22 ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients Lu, Jun Zhang, Yanwei Lou, Yuqing Yan, Bo Zou, Benkun Hu, Minjuan Wang, Yanan Chen, Ya Yang, Zhengyu Wang, Huimin Zhang, Wei Han, Baohui Front Genet Genetics Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for response stratification still need further screening. In the present study, a total of 399 patients with high-quality ctDNA profiling results were included. The mutation status of ubiquitin-like conjugation (UBL) biological process genes (including ABL1, APC, LRP6, FUBP1, KEAP1, and TOP2A) and clinical information were further integrated. The results suggested that the patients with the clinical characteristics of male or history of smoking had a higher frequency of UBL mutation positivity [UBL (+)]; the patients who were UBL (+) had shorter progression-free survival (PFS) (1.69 vs. 3.22 months, p = 0.0007) and overall survival (8.61 vs. 16.10 months, p < 0.0001) than those patients with UBL mutation negativity [UBL (–)]; and more promising predictive values were shown in the smoker subgroup and ≤ 3 metastasis subgroup. More interestingly, we found the predictor has more performance in TP53-negative cohorts [training in an independent POPLAR and OAK cohorts (n = 200), and validation in an independent MSKCC cohort (n = 127)]. Overall, this study provides a predictor, UBL biological process gene mutation status, not only for identifying NSCLC patients who may respond to atezolizumab therapy but also for screening out the potential NSCLC responders who received other immune checkpoint inhibitors. Frontiers Media S.A. 2021-09-07 /pmc/articles/PMC8452871/ /pubmed/34557222 http://dx.doi.org/10.3389/fgene.2021.723670 Text en Copyright © 2021 Lu, Zhang, Lou, Yan, Zou, Hu, Wang, Chen, Yang, Wang, Zhang and Han. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Lu, Jun Zhang, Yanwei Lou, Yuqing Yan, Bo Zou, Benkun Hu, Minjuan Wang, Yanan Chen, Ya Yang, Zhengyu Wang, Huimin Zhang, Wei Han, Baohui ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients |
title | ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients |
title_full | ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients |
title_fullStr | ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients |
title_full_unstemmed | ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients |
title_short | ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients |
title_sort | ctdna-profiling-based ubl biological process mutation status as a predictor of atezolizumab response among tp53-negative nsclc patients |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452871/ https://www.ncbi.nlm.nih.gov/pubmed/34557222 http://dx.doi.org/10.3389/fgene.2021.723670 |
work_keys_str_mv | AT lujun ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT zhangyanwei ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT louyuqing ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT yanbo ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT zoubenkun ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT huminjuan ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT wangyanan ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT chenya ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT yangzhengyu ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT wanghuimin ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT zhangwei ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients AT hanbaohui ctdnaprofilingbasedublbiologicalprocessmutationstatusasapredictorofatezolizumabresponseamongtp53negativensclcpatients |